Clinical research blog
Explore our blog for insights into the big questions in precision medicine and clinical research.
In the age of advanced medical treatments, achieving health equity—in which every individual has the chance to attain their highest level of health regardless of background—is a fundamental yet unmet goal. Despite good intentions, healthcare systems globally face significant challenges in providing equal access and quality of care to all communities.
With Parkinson's disease affecting millions worldwide, the need for enhanced research is both critical and immediate to improve patient outcomes and quality of life. Here, we showcase a curated selection of recent advancements in Parkinson's research.
We recently had the privilege of hosting a booth and speaking in the Precision Medicine World Conference (PMWC) 2024, an event that stands at the intersection of technology, medicine, and research. This gathering of the minds is where the future of healthcare is debated, shaped, and set into motion. Our team returned invigorated by the discussions, collaborations, and insights that PMWC fostered, reflecting a shared ambition to redefine the boundaries of personalised medicine. In this recap, we share three pivotal insights that resonated with us and will continue to shape our vision for the future of precision medicine.
In the realm of clinical genetics, the surge in digital health technology adoption has been remarkable. These innovations, ranging from chatbots assisting with patient admissions to sophisticated machine learning algorithms enhancing genomic analysis and reporting, are revolutionising the delivery of genetic services. They are not only streamlining operations but also ensuring consistent access to healthcare. The abundance of data and the advancement of precision medicine necessitate a digital approach to healthcare interactions, fostering broader access and more tailored care.
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Daniel Barvin and Dr. Paul Wicks, offered an in-depth exploration of the challenges and advancements in the field of ALS (Amyotrophic Lateral Sclerosis), particularly focusing on the genetic forms of the disease.
In the rapidly advancing realm of precision medicine, healthcare professionals (HCPs) are witnessing a transformative shift in their roles. This approach, which tailors treatment to the individual's genetic makeup, lifestyle, and environment, demands a new set of skills and knowledge from HCPs – including physicians, nurses, and pharmacists. They are now at the forefront of integrating complex genetic information into patient care, navigating ethical dilemmas, and maintaining an up-to-date understanding of technological innovations. This blog post explores how precision medicine is reshaping the responsibilities and expertise of HCPs, and what this means for patient care.
- Sano Genetics is the only software platform tailored to running precision medicine clinical trials, leveraging AI to manage all aspects from design to patient recruitment, to genetic and other biomarker testing and patient engagement
- Precision medicine is a fast-growing category - today more than 30% of trials are precision-driven which is predicted to reach 80% by the end of the decade
- Sano Genetics is experiencing huge demand for its product, experiencing 5x growth ARR year-on-year and now serving four of the major pharmaceutical companies
- New funding brings the total raised by the company to $22M to help it meet demand and further automate its processes
In the realm of healthcare, a pivotal shift is taking place: the growing collaboration between academia, biotechnology, and pharmaceutical industries in the field of precision medicine. This evolving partnership is more than a trend; it's transforming how we approach the development of new drugs and treatments.
In the ever-evolving field of rare disease research, it's crucial to remain informed about the latest progress. At Sano, our commitment is to stay ahead of these developments. We are excited to offer a curated overview of some of the most significant advancements in rare disease research from the past few months.
In the rapidly evolving world of healthcare, a profound transformation is taking place at the intersection of Artificial Intelligence (AI) and genomics. This convergence is not just a fleeting trend; it's a fundamental shift in how we approach medicine, diagnosis, and treatment. Our latest whitepaper explores this significant development, shedding light on how AI is unlocking new possibilities in genomic medicine.